Orthocell Limited (ASX:OCC)
Australia
· Delayed Price · Currency is AUD | Market Cap | 275.16M |
| Revenue (ttm) | 7.55M |
| Net Income (ttm) | -8.57M |
| Shares Out | 271.09M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,619 |
| Average Volume | 608,310 |
| Open | 1.015 |
| Previous Close | 1.015 |
| Day's Range | 1.010 - 1.035 |
| 52-Week Range | 0.920 - 1.790 |
| Beta | -0.24 |
| RSI | 38.68 |
| Earnings Date | Dec 1, 2025 |
About Orthocell
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company ... [Read more]
Financial Performance
In 2025, Orthocell's revenue was 7.55 million, an increase of 42.05% compared to the previous year's 5.32 million. Losses were -8.57 million, 19.3% more than in 2024.
Financial StatementsNews
Perth biotech Orthocell targets US growth with $25m capital injection
New shares were being offered at $1.30 per share – a 9.1 per cent discount to the last trading price via sole lead manager Canaccord Genuity.
Perth’s billionaire set is piling into this little-known medtech
The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break into the US.